BioSpace News Archive

Natera, Inc. announced that Matthew Rabinowitz, co-founder and Executive Chairman of Natera, together with his family’s trust, have recently acquired a total of 470,000 shares of Natera stock through the purchase of additional shares on the open market and from the exercise of stock options.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2022 financial results.

Syros Pharmaceuticals today reported financial results for the quarter ended March 31, 2022 and provided a corporate update.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 2022.

Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors.

Miravo Healthcare ™ Announces First Quarter 2022 Results.

Affinia Therapeutics today announced results from preclinical studies presented in an oral session at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference.

Imago BioSciences, Inc. announced that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in three upcoming investor conferences.

Humacyte, Inc. announced that Dale Sander, Chief Financial Officer, and Heather Prichard, Ph.D., Chief Operating Officer, will deliver a corporate presentation in-person at the H.C. Wainwright Global Investment Conference taking place both virtually and in-person at the Fontainebleau Hotel in Miami, on May 24, 2022, at 10:30 a.m. ET.